Literature DB >> 35355760

Comparative Study on the Efficacy of MF 59, ISA70 VG, and Nano-Aluminum Hydroxide Adjuvants, Alone and with Nano-Selenium on Humoral Immunity Induced by a Bivalent Newcastle+Avian Influenza Vaccine in Chickens.

M Radmehri1, A Talebi1, A Ameghi Roudsari2, S M Mousaviyan3, M A J Gholipour3, M Taghizadeh2.   

Abstract

Newcastle disease (ND) and Avian influenza (AI) are the major problems and the most economically important viral diseases in the poultry industry; therefore, vaccination against these diseases is considered one of the most effective ways of prevention. Extensive studies have been conducted to improve the performance of vaccines, and one of the major achievements of these studies is the preparation of adjuvants as stimulants of the immune system and one of the most important compounds in killed vaccines. An immunogenicity comparison of three adjuvants including, ISA70VG, Nano-Aluminum Hydroxide (Nano-Alum), and MF59 alone or with Nano-Selenium (Nano-Se), was performed using bivalent Newcastle plus Avian Influenza (ND+AI) killed vaccine. In this study, 105 specific-pathogen-free chicks (Ross-308) were divided into 7 treatments, including T1 (control group), T2 (ISA70VG), T3 (ISA70VG plus Nano-Se), T4 (Nano-Alum Hydroxide), T5 (Nano-Alum+Nano-Se), T6 (MF59), and T7 (MF59+Nano-Se). The vaccine was injected subcutaneously on day 21 in the back of the neck area. The blood samples were taken on days 14, 21, 28, 35, 42, and 49 post-vaccination. Serums of the samples were titrated by the haemagglutination inhibition (HI) test against Newcastle and Avian influenza. Based on the results, the highest HI test titers were observed for the T2 and T3 treatments, while the T6 and T7 treatments had the lowest titers. Moreover, regardless of the type of the adjuvants, adding Nano-Se increased the antibody titer in the vaccinated groups. In conclusion, a combination of the ISA70VG adjuvant and Nano-Se induced excellent antibody titers using bivalent ND+AI killed vaccine.

Entities:  

Keywords:  Adjuvant; Avian influenza; ISA 70 VG; MF59; Nano-Aluminum Hydroxide; Nano-Selenium; Newcastle disease

Mesh:

Substances:

Year:  2021        PMID: 35355760      PMCID: PMC8934087          DOI: 10.22092/ari.2021.356666.1887

Source DB:  PubMed          Journal:  Arch Razi Inst        ISSN: 0365-3439


  25 in total

Review 1.  Vaccine adjuvants: current state and future trends.

Authors:  Nikolai Petrovsky; Julio César Aguilar
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

2.  Heat inactivation of avian influenza and Newcastle disease viruses in egg products.

Authors:  David E Swayne; Joan R Beck
Journal:  Avian Pathol       Date:  2004-10       Impact factor: 3.378

3.  Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Authors:  Hiroyuki Fukase; Hidetoshi Furuie; Yuji Yasuda; Ryoya Komatsu; Kenji Matsushita; Taketsugu Minami; Yutaka Suehiro; Hiroshi Yotsuyanagi; Haruko Kusadokoro; Hiroshi Sawata; Noriko Nakura; Maria Lattanzi
Journal:  Vaccine       Date:  2012-04-01       Impact factor: 3.641

4.  Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Authors:  Markus Knuf; Geert Leroux-Roels; Hans C Rümke; Katia Abarca; Luis Rivera; Maria Lattanzi; Paola Pedotti; Ashwani Arora; Dorothee Kieninger-Baum; Giovanni Della Cioppa
Journal:  Vaccine       Date:  2014-11-11       Impact factor: 3.641

5.  A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

Authors:  Stephan A Bart; Matthew Hohenboken; Giovanni Della Cioppa; Vas Narasimhan; Philip R Dormitzer; Niranjan Kanesa-Thasan
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

6.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.

Authors:  Chia-Ying Wu; Ching-Yuan Chang; Hsiu-Hua Ma; Chiung-Wen Wang; Yung-Tsung Chen; Pei-Wen Hsiao; Ching-Chuan Chang; Chi-Hsien Chan; Chung-Cheng Liu; Juine-Ruey Chen
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

Review 8.  MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

Authors:  Derek T O'Hagan
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

9.  Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles.

Authors:  Xinran Li; Abdulaziz M Aldayel; Zhengrong Cui
Journal:  J Control Release       Date:  2013-11-01       Impact factor: 9.776

Review 10.  Vaccine Adjuvants: from 1920 to 2015 and Beyond.

Authors:  Alberta Di Pasquale; Scott Preiss; Fernanda Tavares Da Silva; Nathalie Garçon
Journal:  Vaccines (Basel)       Date:  2015-04-16
View more
  1 in total

Review 1.  Protective and detoxifying effects conferred by selenium against mycotoxins and livestock viruses: A review.

Authors:  Manxin Fang; Wei Hu; Ben Liu
Journal:  Front Vet Sci       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.